AZBio.org | Arizona BioIndustry Association - Part 5

Click the image for the latest news about AZBio Members
Click the image to visit the program page and watch the encore presentation
Click the image to access the AZBW 2020 videos and recap
Use the links above to access COVID-19 Resources and Information
We CAN slow the spread of COVID-19. Click the image to learn more
Click the image to learn more about AZBio Membership
Click the image to enter the AZBio Career Center
AZBio Members save with BIO Business Solutions. Click the image to learn more.
Click the image to visit AZBio.TV

AZBio is committed to building a top-tier life science industry in Arizona.

Arizona’s bioscience industry is growing rapidly and reached nearly 30,000 jobs spanning 2,160 business establishments in 2018. Industry employment has grown by 15 percent since 2016—twice the growth rate of the nation—with each of the five major subsectors adding jobs during the period. Arizona’s universities conducted nearly $580 million in R&D activities in bioscience-related fields in 2018, fueled in part by steadily increasing NIH awards to Arizona institutions since 2016. Venture capital investments in Arizona bioscience companies increased in 2019, and during the 2016-19 period totaled $349 million. Arizona inventors have been awarded 2,178 bioscience-related patents since 2016, among the second quintile of states in patent activity.

A key component in Arizona’s life science ecosystem, the Arizona Bioindustry Association (AZBio) is the only statewide organization exclusively focused on Arizona’s bioscience industry. AZBio membership includes patient advocacy organizations, life science innovators, educators, healthcare partners and leading business organizations. AZBio is the statewide affiliate of the Biotechnology Innovation Organization (BIO) and works in partnership with AdvaMed, MDMA, and PhRMA to advance innovation and to ensure that the value delivered from life-changing and life-saving innovation benefits people in Arizona and around the world.

Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study

First interim analysis included 95 participants with confirmed cases of COVID-19 Phase 3 study met statistical criteria with a vaccine efficacy of 94.5% (p <0.0001) Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 […]

Managing the microbiome raises new hope for autism

In new research appearing in the journal mSphere, Rosa Krajmalnik-Brown, James Adams and their colleagues highlight the crucial importance of bacterial microbes in the human gut for the diagnosis and treatment of ASD. In September of 2020, Rosa Krajmalnik-Brown was honored as the Arizona Bioscience Researcher of the Year

GT Medical Technologies Announces First Patient Treated in Registry Trial of GammaTile Therapy for Brain Tumors

Study to Enroll 600 Patients and Evaluate Real-World Clinical and Patient Reported Outcomes Across All Brain Tumor Types First Patient Enrolled by Vidant Health in Greenville, N.C.

Lilly’s neutralizing antibody bamlanivimab (LY-CoV555) receives FDA emergency use authorization for the treatment of recently diagnosed COVID-19

Bamlanivimab is authorized for treatment of recently diagnosed, mild to moderate COVID-19 in high-risk patients U.S. government will allocate 300,000 doses of bamlanivimab to high-risk patients, with no out-of-pocket costs for the medication